Cover Image
市場調查報告書

氣喘預防藥的全球市場:2015年∼2019年

Global Preventive Asthma Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 254969
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
氣喘預防藥的全球市場:2015年∼2019年 Global Preventive Asthma Drugs Market 2015-2019
出版日期: 2015年10月07日 內容資訊: 英文 81 Pages
簡介

全球氣喘預防藥市場預測在2014年∼2019年間將以複合成長率(CAGR)5.20%的速度成長。

本報告提供全球氣喘預防藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點

第5章 產品系列

  • Accolate
  • Pulmicort
  • Symbicort
  • Xolair
  • Advair
  • Anoro Ellipta
  • Arnuity Ellipta
  • Breo Ellipta
  • Flovent
  • Serevent
  • Ventolin
  • Asmanex
  • Foradil
  • Dulera
  • Singulair

第6章 疾病概要

  • 疾病的理解
  • 症狀
  • 病理生理學
  • 流行病學
  • 診斷
  • 管理

第7章 產品研發線

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔:藥物群別

第10章 吸入類固醇藥 (ICS) /長效型吸入β2刺激藥 (LABA) 組合藥物

第11章 免疫抑制劑

第12章 白三烯拮抗劑

第13章 肥大細胞穩定劑

第14章 吸入皮質類固醇劑

第15章 地理區分

  • 各地區
  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第16章 推動市場要素

第17章 推動因素的影響

第18章 市場課題

第19章 推動因素與課題的影響

第20章 市場趨勢

第21章 業者情勢

  • 競爭模式
  • 其他卓越供應商

第22章 主要供應商分析

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

第23章 附錄

第24章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR7196

About asthma

According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations.

Technavio's analysts forecast the global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of the following classes of drugs used to treat asthma:

  • Immunosuppressants
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Corticosteroids
  • Combination of LABA/ ICS

This report includes a discussion of the market in the following three regions:

  • Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

Other Prominent Vendors

  • Abbott
  • Amgen
  • AptarGroup
  • Biotest
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cytos
  • Dainippon Sumitomo
  • Medicinova
  • Mylan
  • Novartis
  • Orchid Chemicals and Pharmaceuticals
  • Pfizer
  • Rottapharm Madaus
  • Skyepharma
  • Sosei
  • Sunovion
  • Teva Pharmaceutical
  • Theravance
  • Vectura

Key market driver

  • High prevalence of asthma
  • For a full, detailed list, view our report

Key market challenge

  • Unknown disease etiology
  • For a full, detailed list, view our report

Key market trend

  • Growing popularity of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Product profiles

  • Accolate
  • Pulmicort
  • Symbicort
  • Xolair
  • Advair
  • Anoro Ellipta
  • Arnuity Ellipta
  • Breo Ellipta
  • Flovent
  • Serevent
  • Ventolin
  • Asmanex
  • Foradil
  • Dulera
  • Singulair

PART 06: Disease overview

  • Understanding the disease
  • Symptoms
  • Pathophysiology
  • Epidemiology
  • Diagnosis
  • Management

PART 07: Pipeline Portfolio

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by class of drug

PART 10: ICS/LABA combination

  • Global ICS/LABA combination market

PART 11: Immuno-suppressants

  • Global immunosuppressants market

PART 12: Leukotriene antagonists

  • Global leukotriene antagonists market

PART 13: Mast cell stabilizers

  • Global mast cell stabilizers market

PART 14: Inhaled corticosteroids

  • Global inhaled corticosteroids market

PART 15: Geographical segmentation

  • Global preventive asthma drugs market by geography 2014-2019
  • Preventive asthma drugs market in Americas
  • Preventive asthma drugs market in EMEA
  • Preventive asthma drugs market in APAC

PART 16: Market drivers

PART 17: Impact of drivers

PART 18: Market challenges

PART 19: Impact of drivers and challenges

PART 20: Market trends

PART 21: Vendor landscape

  • Competitive scenario
  • Other and future prominent vendors

PART 22: Key vendor analysis

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

PART 23: Appendix

  • List of abbreviations

PART 24: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Major diagnostic procedures for asthma
  • Exhibit 03: Major drugs under development for asthma
  • Exhibit 04: Global preventive asthma drugs market ($ millions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Segmentation of global preventive asthma drugs market by class of drug
  • Exhibit 07: Segmentation of global preventive asthma drugs market by class of drug 2014
  • Exhibit 08: Global preventive asthma drugs market: Market share by class of drug 2014-2019 ($ millions)
  • Exhibit 09: Global ICS/LABA combination market 2014-2019 ($ millions)
  • Exhibit 10: Global immunosuppressants market 2014-2019 ($ millions)
  • Exhibit 11: Global leukotriene antagonists market 2014-2019 ($ millions)
  • Exhibit 12: Global mast cell stabilizers market 2014-2019 ($ millions)
  • Exhibit 13: Global corticosteroids market 2014-2019 ($ millions)
  • Exhibit 14: Global preventive asthma drugs market by geography 2014
  • Exhibit 15: Global preventive asthma drugs market: Market share by region 2014-2019 ($ millions)
  • Exhibit 16: Preventive asthma drugs market in Americas 2014-2019 ($ millions)
  • Exhibit 17: Preventive asthma drugs market in EMEA 2014-2019 ($ millions)
  • Exhibit 18: Impact of drivers
  • Exhibit 19: Impact of drivers and challenges
  • Exhibit 20: Sales of Pulmicort in US 2011-2014 ($ millions)
  • Exhibit 21: Global sales of Pulmicort 2011-2014 ($ millions)
  • Exhibit 22: AstraZeneca: Key takeaways
  • Exhibit 23: Sales of Xolair in the US 2011-2014 ($ millions)
  • Exhibit 24: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 25: Global sales of Ventolin 2011-2014 ($ millions)
  • Exhibit 26: Global sales of Flovent 2011-2014 ($ millions)
  • Exhibit 27: Global sales of Advair 2011-2014 ($ millions)
  • Exhibit 28: Global sales of Serevent 2011-2014 ($ millions)
  • Exhibit 29: GlaxoSmithKline: Key takeaways
  • Exhibit 30: Global sales of Asmanex 2011-2013 ($ millions)
  • Exhibit 31: Global sales of Dulera 2011-2013 ($ millions)
  • Exhibit 32: Global sales of Singulair 2011-2013 ($ millions)
  • Exhibit 33: Merck: Key takeaways
  • Exhibit 34: Sales of Xolair (ex-US) 2011-2014 ($ millions)
  • Exhibit 35: Key takeaways: Novartis
  • Exhibit 36: AstraZeneca: Business segmentation by revenue 2014
  • Exhibit 37: AstraZeneca: Business segmentation by revenue 2013 and 2014
  • Exhibit 38: AstraZeneca: Geographical segmentation by revenue 2014
Back to Top